Poster Presentation Joint 2016 COSA and ANZBCTG Annual Scientific Meeting

Trans-arterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC): Experience from an Australian tertiary care centre (#238)

Minmin Li 1 , Eugene Wong 1 , Sarah J Zardawi 1 , David L Chan 1 , Matthew Wong 2 , Adrian Lee 1 , Helen Westman 3 , Richard Maher 4 5 , Stephen Clarke 1 , Nick Pavlakis 1
  1. Department of Medical Oncology, Royal North Shore Hospital, Sydney, NSW, Australia
  2. Department of Medical Oncology, Gosford Hospital, Gosford, NSW, Australia
  3. North Shore Private Hospital, Sydney, NSW, Australia
  4. Department of Radiology, Royal North Shore Hospital, Sydney, NSW, Australia
  5. Department of Radiology, Royal North Shore Hospital, Sydney, NSW, Australia

Aim

To evaluate TACE procedures regarding its efficacy and safety in our local institution; and identify possible predictors for TACE therapy that influence outcomes.

Methods

A retrospective analysis of 84 patients who received treatment with TACE for HCC between 2007 and 2015 at our centre was performed. Primary outcomes measured were progression-free survival, overall survival and complication rates.

Results

The median progression-free survival was 12.0 months, with median overall survival time being 30.7 months. An alpha-fetoprotein (AFP) response ratio of greater than 50% was associated with better progression-free and overall survival. The patient’s Child-Pugh score and unilobar involvement also correlated with overall survival in multivariate analysis. No significant post procedural complications were encountered.

Conclusions

TACE is safe and effective in the management of HCC. A fall of 50% in AFP after TACE was predictive of better progression-free and overall survival.